At the Global Ethics Forum, a leading platform that convenes stakeholders from various sectors to discuss peace, sustainability, and ethical leadership, the Chairman of QingSong Health, China’s premier healthcare solutions technology platform, delivered a compelling keynote address. The Forum serves as a multisectoral space for dialogue among institutions, policymakers, and experts, aimed at envisioning a future that emphasizes ethical engagement for better global outcomes.
Founded in 2014, QingSong Health is dedicated to providing integrated healthcare solutions in China, serving over 30 million families. The platform combines health education, advanced technologies, and effective health management to offer a comprehensive range of services, including health consultations, disease prevention, and rehabilitation care.
In her address, the Chairman shared three key insights on the role of Artificial Intelligence (AI) in healthcare:
AI as a Bridge Builder: The Chairman underscored AI’s role in enhancing access to healthcare, noting a staggering growth of over 200% in telemedicine consultations globally. This surge connects individuals to specialized medical expertise, addressing disparities in access to care. QingSong Health’s AI tool, Dr. GPT, exemplifies this innovation by efficiently handling inquiries about 3,800 common diseases, ensuring that critical health information is readily accessible to all users.
AI in Prevention: She stressed the importance of AI-driven early intervention, which can reduce healthcare costs by up to 30% while significantly improving patient outcomes. By integrating traditional healthcare wisdom with cutting-edge technology, QingSong Health’s innovative health detectors empower individuals to engage in proactive wellness and preventive care, ultimately aiming to avert health issues before they arise.
Ethical AI:The Chairman highlighted that ethical considerations are paramount in AI development. Guided by Confucian values that emphasize empathy and respect for human dignity, QingSong Health is committed to creating AI solutions that protect privacy and promote ethical standards. The company collaborates with Globethics to advocate for the responsible use of AI in healthcare, ensuring alignment with global best practices for ethical engagement.
In conclusion, the Chairman asserted that “AI offers a pathway to a healthier future, bridging healthcare gaps while reinforcing ethical standards.” She called on global leaders to foster ongoing dialogue inspired by the Global Ethics Forum’s emphasis on inclusive engagement and sustainable development, urging them to work collaboratively towards a brighter future for all.
SOURCE Qingsong Health Corporation
The post QingSong Health Chairman Speaks at Global Ethics Forum in Geneva: Advancing Ethical Leadership in Healthcare appeared first on HIPTHER Alerts.

 
Recently, one of the most respected media firms in the financial services industry, Finance Magnates released its latest data report for the Q2 2024, showing ATFX achieved an impressive global ranking of 4th in trading volume on the MT4/MT5 platforms, with a total volume reaching $765.1 billion. This milestone underscores ATFX’s strong competitive edge in the global financial markets and highlights significant growth in trading activity.
Compared to the previous quarter, ATFX’s trading volume in Q2 2024 saw a significant increase of 22.45%, and an astonishing 43.75% year-on-year growth. These impressive growth rates are not only a solid foundation for the company’s continued success but also a vivid reflection of its expanding business footprint and growing market influence.
Breaking down the product trends, the precious metals category grew by 26.2% compared to Q1 2024 and 79.2% compared to Q2 2023. The indices category saw a 99.38% increase compared to Q1 2024 and a 14.58% increase compared to Q2 2023. The stocks category experienced a staggering 457.82% growth compared to Q1 2024 and a 167.89% increase compared to Q2 2023. The energy category grew by 23.03% compared to Q1 2024, among others.
For a long time, ATFX’s trading volume has consistently ranked among the top ten globally, a testament to the brand’s strength and market competitiveness. This outstanding achievement also reflects our years of deep cultivation in the financial market, through building an integrated model of investment education, services, and tools to serve global clients. Looking ahead, ATFX will continue to prioritize customer needs, providing comprehensive and high-quality trading support services.
The post ATFX Ranks 4th Globally in Q2 2024 Trading Volume with a Remarkable 43.75% Year-Over-Year Growth appeared first on HIPTHER Alerts.

 
SciBase Holding AB (“SciBase”) (STO: SCIB), pioneering prevention and prediction in dermatology announces that key US clinicians and scientists reached consensus on Nevisense and how it can significantly enhance the diagnostic assessment and clinical decision-making for early melanoma at point of care. Nevisense is an AI-driven, non-invasive technology, and the only FDA-approved device for early skin cancer detection.
The consensus report evaluated several technologies for melanoma diagnosis and supports the use of Nevisense for its ability to significantly enhance clinician’s diagnostic assessment of atypical moles by non-invasively providing them with critical information at point of care. The report was published in the Journal of Drugs in Dermatology (JDD) – a peer-reviewed, dermatology journal. The report co-authors included top US clinicians such as Seemal R. Desai, MD, Keyvan Nouri, MD, Aaron S. Farberg, MD, Gary Goldenberg, MD, Mark Lebwohl, MD, and Darrell Rigel, MD, MS, Brian Berman, MD, PhD, Brad Glick, DO, MPH, Mark Nestor, MD, PhD, MBA, and Theodore Rosen, MD.
“I am so excited that this renowned panel of leading dermatologists has endorsed Nevisense as an important tool for early detection of melanoma. This is a significant step forward for SciBase in our US commercialization process,” says Pia Renaudin, CEO of SciBase.
“Melanoma is one of the top 5 most common cancers in the US and is the main cause of skin cancer deaths in the United States. Early detection is critical to survival and one of the few ways to improve clinical outcomes for patients. With melanoma, timing and the earliest detection possible can make a significant positive impact on survival rates and outcomes. For these reasons, we as clinicians can provide our patients with AI-powered Nevisense, which is an advanced technology that enhances early detection while easily integrating at the point-of-care,” said Dr. Darrell Rigel, board-certified dermatologist, Clinical Professor of Dermatology Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, Adjunct Professor, UT Southwestern Medical School, Consultant Dermatologist, Cooper Clinic. Dr. Rigel served as President of the American Academy of Dermatology, the American Academy of Dermatology Association, the American Society for Dermatologic Surgery and the American Dermatological Association, as a Director of the American Board of Dermatology, and is the current Chair of SkinPAC (the American Academy of Dermatology Association’s political action committee).
“Nevisense is a powerful combination of human intelligence and artificial intelligence working together to improve clinical outcomes.  At Goldenberg Dermatology, we strive to provide our patients with the highest standard of care with the most advanced technology. Nevisense helps clinicians identify more atypical pigmented skin lesions, which in turn helps increase detection rates. The clinically proven and validated science, and ease of practical integration were all key to reaching consensus,” said Dr. Gary Goldenberg, board certified dermatologist and dermatopathologist, CEO and founder of Goldenberg Dermatology PC, and Assistant Clinical Professor of Dermatology at the Icahn School of Medicine at Mount Sinai Hospital in New York City.
The post New US Consensus Report supports Nevisense appeared first on HIPTHER Alerts.